Feb 17, 2020 / 03:00AM GMT
Operator
Ladies and gentlemen, good day and welcome to the Q3 FY '20 Earning Conference Call of Glenmark Pharmaceuticals Limited.
(Operator Instructions) Please note that this conference is being recorded.
I would now like to hand the conference over to Mr. Jason D'souza. Thank you. And over to you, sir.
Jason D'souza - Glenmark Pharmaceuticals Limited - Senior VP & Head of Corporate Strategy
Thank you, moderator. Welcome to Glenmark's Q3 Earnings Call.
First, a review of operations for the quarter ended December 31, 2019.
For the third quarter of FY '19/'20, Glenmark's consolidated revenue was INR 27,355 million, as against INR 25,500 million, recording an increase of 7.07%. For the 9 months ended December 31, 2019, Glenmark's consolidated revenue was at INR 78,734 million, recording an increase of 7.83%.
India business. Sales from the formulation business in India for the third quarter was at 7,888.39 million, as against INR 6,675 million, recording a growth of 18.17%.
The India business
Q3 2020 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Feb 17, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers